Search Result

Results for "

protein storage diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (4) Autophagy (5) Biochemical Assay Reagents (2) Endogenous Metabolite (6) Glycosidase (1) Isotope-Labeled Compounds (1) MOFs (1) Opioid Receptor (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (5) Inflammation/Immunology (1) Metabolic Disease (6) Neurological Disease (8)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2581

Phytic acid sodium salt 1 Publications Verification myo-Inositol, hexakisdihydrogen phosphate sodium salt; Inositol hexaphosphate sodium salt	MOFs Endogenous Metabolite Amyloid-β Autophagy	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Phytic acid (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) sodium salt is an orally active compound. Phytic acid sodium salt can be derived from the seeds of legumes. Phytic acid sodium salt is a [PO4] ³- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid sodium salt attenuates Aβ oligomers and upregulates autophagy protein. Phytic acid sodium salt can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research .

HY-N0814

Phytic acid (50% w/w in water) 1 Publications Verification Inositol hexaphosphate; SNF472 free acid	Endogenous Metabolite Amyloid-β Autophagy	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Phytic acid (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) is an orally active compound. Phytic acid can be derived from the seeds of legumes. Phytic acid is a [PO4] ³- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid attenuates Aβ oligomers and upregulates autophagy protein. Phytic acid can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research .

HY-153830

LacCer (d18:1/16:0) C16 Lactosylceramide (d18:1/16:0)	Endogenous Metabolite	Neurological Disease Metabolic Disease
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-D1056F

Biotin-Lipopolysaccharide, from E.coli O111:B4 Biotin-LPS, from Escherichia coli (O111:B4)	Biochemical Assay Reagents	Inflammation/Immunology
Biotin-Lipopolysaccharide, from E.coli O111:B4 (Biotin-LPS, from Escherichia coli (O111:B4)) is a biotin-conjugated Lipopolysaccharide (LPS) (HY-D1056A1) that can be coupled with streptavidin protein. Biotin-Lipopolysaccharide, from E.coli O111:B4 can be used to identify Lipopolysaccharide ligands. Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides, from E. coli O111:B4 can also induce M1-type polarization in mouse macrophages . It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

HY-N2580

Zinc Phytate 1 Publications Verification	Endogenous Metabolite Amyloid-β Autophagy	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Zinc Phytate (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) is an orally active compound. Zinc Phytate can be derived from the seeds of legumes. Zinc Phytate is a [PO4] ³- storage depot and precursor for other inositol phosphates and pyrophosphates. Zinc Phytate attenuates Aβ oligomers and upregulates autophagy protein. Zinc Phytate can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research .

HY-13101

MCOPPB trihydrochloride 1 Publications Verification	Opioid Receptor Autophagy	Cardiovascular Disease Neurological Disease
MCOPPB trihydrochloride is a NOP/ORL1 G protein-coupled receptor agonist and autophagy inhibitor that can cross the blood-brain barrier. MCOPPB trihydrochloride clears senescent cells, regulates locomotion, lipid storage and immune responses, and inhibits fibrosis and angiogenesis. MCOPPB trihydrochloride blocks autophagic flux, induces changes in locomotion and lipid storage, and activates the stress-responsive immune transcription network, thereby improving post-infarction cardiac function and exerting anxiolytic effects. MCOPPB trihydrochloride can be applied to research fields such as aging-related diseases and ischemic heart failure .

HY-W056439

N-Boc-3-hydroxy-1,2,3,6-tetrahydropyridine	Glycosidase	Neurological Disease
N-Boc-3-hydroxy-1,2,3,6-tetrahydropyridine can increase the activity of β-glucocerebrosidase by 20%. N-Boc-3-hydroxy-1,2,3,6-tetrahydropyridine can be used in the study of lysosomal storage diseases and other protein storage diseases .

HY-153830S

LacCer (d18:1/16:0)-d3 C16 Lactosylceramide (d18:1/16:0)-d₃	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Metabolic Disease
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d₃ is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-181448

Phytic acid hexalithium Inositol hexaphosphate hexalithium; SNF472 hexalithium	Endogenous Metabolite Amyloid-β Autophagy	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Phytic acid (Inositol hexaphosphate hexalithium) hexalithium is an orally active compound. Phytic acid hexalithium can be derived from the seeds of legumes. Phytic acid is a [PO4] ³- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid hexalithium attenuates Aβ oligomers and upregulates Autophagy protein. Phytic acid hexalithium can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research .

HY-P2858H

β-Mannosidase, Streptomyces coelicolor	Biochemical Assay Reagents	Others
β-Mannosidase, Streptomyces coelicolor (EC 3.2.1.25) catalyses the following chemical reaction:Hydrolysis of terminal, non-reducing beta-D-mannose residues in beta-D-mannosides. This gene encodes a member of the glycosyl hydrolase 2 family. The encoded protein localizes to the lysosome where it is the final exoglycosidase in the pathway for N-linked glycoprotein oligosaccharide catabolism. Mutations in this gene are associated with beta-mannosidosis, a lysosomal storage disease that has a wide spectrum of neurological involvement.

Cat. No.	Product Name	Type

HY-D1056F

Biotin-Lipopolysaccharide, from E.coli O111:B4 Biotin-LPS, from Escherichia coli (O111:B4)	Biochemical Assay Reagents
Biotin-Lipopolysaccharide, from E.coli O111:B4 (Biotin-LPS, from Escherichia coli (O111:B4)) is a biotin-conjugated Lipopolysaccharide (LPS) (HY-D1056A1) that can be coupled with streptavidin protein. Biotin-Lipopolysaccharide, from E.coli O111:B4 can be used to identify Lipopolysaccharide ligands. Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides, from E. coli O111:B4 can also induce M1-type polarization in mouse macrophages . It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Biotin-Lipopolysaccharide, from E.coli O111:B4

Biotin-LPS, from Escherichia coli (O111:B4)

Biochemical Assay Reagents

Biotin-Lipopolysaccharide, from E.coli O111:B4 (Biotin-LPS, from Escherichia coli (O111:B4)) is a biotin-conjugated Lipopolysaccharide (LPS) (HY-D1056A1) that can be coupled with streptavidin protein. Biotin-Lipopolysaccharide, from E.coli O111:B4 can be used to identify Lipopolysaccharide ligands. Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides, from E. coli O111:B4 can also induce M1-type polarization in mouse macrophages .
It is recommended to prepare a solution with concentration ≥2 mg/mL. Vortex thoroughly for more than 10 minutes. Due to the adsorption characteristics of LPS, silanized container or low adsorption centrifuge tubes should be used for aliquoting and storage, and mix thoroughly before use.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2581

Phytic acid sodium salt 1 Publications Verification myo-Inositol, hexakisdihydrogen phosphate sodium salt; Inositol hexaphosphate sodium salt	Structural Classification Natural Products Zea mays L. Classification of Application Fields Gramineae Other Diseases Plants Disease Research Fields Source Classification	MOFs Endogenous Metabolite Amyloid-β Autophagy
Phytic acid (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) sodium salt is an orally active compound. Phytic acid sodium salt can be derived from the seeds of legumes. Phytic acid sodium salt is a [PO4] ³- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid sodium salt attenuates Aβ oligomers and upregulates autophagy protein. Phytic acid sodium salt can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research .

HY-N0814

Phytic acid (50% w/w in water) 1 Publications Verification Inositol hexaphosphate; SNF472 free acid	Structural Classification other families Neurological Disease Classification of Application Fields Food Preservation Research Ketones, Aldehydes, Acids Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification Agricultural Research	Endogenous Metabolite Amyloid-β Autophagy
Phytic acid (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) is an orally active compound. Phytic acid can be derived from the seeds of legumes. Phytic acid is a [PO4] ³- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid attenuates Aβ oligomers and upregulates autophagy protein. Phytic acid can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research .

HY-153830

LacCer (d18:1/16:0) C16 Lactosylceramide (d18:1/16:0)	Microorganisms Saccharides Monosaccharides Source Classification	Endogenous Metabolite
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-N2580

Zinc Phytate 1 Publications Verification	Natural Products other families Classification of Application Fields Other Diseases Plants Disease Research Fields Source Classification	Endogenous Metabolite Amyloid-β Autophagy
Zinc Phytate (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) is an orally active compound. Zinc Phytate can be derived from the seeds of legumes. Zinc Phytate is a [PO4] ³- storage depot and precursor for other inositol phosphates and pyrophosphates. Zinc Phytate attenuates Aβ oligomers and upregulates autophagy protein. Zinc Phytate can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research .

Cat. No.	Product Name	Chemical Structure

HY-153830S

LacCer (d18:1/16:0)-d3
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d₃ is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

LacCer (d18:1/16:0)-d3

LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d₃ is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

protein storage diseases

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products